Leqembi: A Promising Ally in Alzheimer's Battle
Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S. regulatory review. More patients showed improvements, and the drug's impact against amyloid plaques was notable.
Eisai and Biogen's Alzheimer's treatment, Leqembi, is demonstrating positive results with prolonged use. New data presented at a recent medical conference reveals that the drug continued to slow disease progression four years into treatment with no additional safety concerns.
The injectable form of Leqembi, currently under review by the U.S. regulatory authorities, stands to offer more convenience to patients. The most significant outcomes were observed in those starting treatment during the early stages of Alzheimer's.
Leqembi has shown efficacy by targeting amyloid plaques, a key Alzheimer's feature, having slowed cognitive decline by 34% after continuous use. Eisai is exploring the drug's potential in pre-symptomatic patients, while the U.S. FDA is evaluating the new formulation for approval by the end of August.
Google News